Please assess the completion status of the following clinical trial:

Trial Title: Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* General good health~* HIV-uninfected~* Normal menstrual cycle. More information can be found in the protocol.~* Creatinine clearance greater than 70 ml/min~* Sexually active. More information can be found in the protocol.~* Normal Pap smear result within 12 months prior to study entry~* Agrees to not participate in other investigational studies~* Willing to use effective forms of contraception. More information can be found in the protocol.~Exclusion Criteria:~* Adverse reaction to either of the study products~* Adverse reaction to latex~* Currently sexually active with a partner with history of adverse reaction to latex~* More than three sexual partners in the month prior to screening~* Pathologic bone fracture not related to trauma~* Last pregnancy outcome within 90 days or less prior to enrollment~* Gynecologic or genital procedure within 90 days of study entry~* Enrollment in other investigational study within 30 days of study entry~* Nontherapeutic injection drug use within 12 months of screening~* Any social or medical condition that, in the opinion of the investigator, would interfere with the study~* Abnormal laboratory values~* Grade 2 or higher genital lesions, erythema, and/or edema or has any other abnormal physical or pelvic exam finding that, in the opinion of the investigator, would interfere with the study~* Kidney, reproductive, or urinary tract infection requiring treatment. More information on this criterion can be found in the protocol.~* Pregnant, breastfeeding, or intend to become pregnant~* Unwilling to comply with study participation requirements, including attendance at all scheduled study visits~* Per participant report, use of the following at enrollment, and/or anticipated use during the period of study participation - use of a diaphragm, vaginal ring, and/or spermicide for contraception, acyclovir or valacyclovir, post-exposure prophylaxis for HIV exposure, TDF/emtricitabine, non-study vaginal products

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
- 2 (Type: EXPERIMENTAL): Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
- 3 (Type: EXPERIMENTAL): Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
- 4 (Type: EXPERIMENTAL): Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
- 5 (Type: EXPERIMENTAL): Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
- 6 (Type: EXPERIMENTAL): Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete